Dairy Australia announces DataGene boss Matthew Shaffer will lead the organisation into a ‘new era' as CEO
Mr Shaffer was selected after an 'extensive' recruitment process for his vision for the organisation, knowledge and passion for the dairy industry, and strong commercial experience in agriculture.
His appointment comes at a time when the dairy industry is facing climate-induced disruptions, fluctuating farmgate prices, high operating costs and global headwinds.
Dairy Australia chair Paul Roderick said Mr Shaffer brings a wealth of experience and a proven ability to deliver meaningful change.
'After consulting farmers around Dairy Australia's strategic direction, we are preparing to launch a new five-year strategy,' he said.
'Matt will contribute to shaping our future direction and play a critical role in implementing a strategy that supports farmers to unlock the potential of their farm business, innovate for future success, while ensuring a sustainable dairy industry.'
Mr Shaffer has extensive experience in agricultural economics and corporate leadership within the dairy industry.
He was most recently chief executive of DataGene, before which he was chief executive of Holstein Australia.
Mr Shaffer also spent time in an international operations role at US-based Hancock Agriculture Investment Group.
He will succeed managing director David Nation — who announced his decision to step down in late 2024 after seven years in the role — on July 16.
Mr Roderick said Mr Nation challenged the status quo and championed initiatives that have had a lasting impact on the dairy industry.
'His leadership in research and innovation through partnerships with DairyBio and DairyFeedbase has been exceptional,' he said.
'He also played a key role in enhancing Dairy Australia's support for the industry's sustainability agenda, building community trust, and strengthening regional connections with farmers.
'Under his guidance, Dairy Australia has become a more people-focused organisation with a clear commitment to delivering value for the industry.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
2 hours ago
- Sky News AU
Coldplay concert cheating scandal: Interim Astronomer CEO embraces company's public spotlight in wake of kiss cam controversy
The interim CEO of AI data operations startup Astronomer has found the silver lining after its former head and human resources director were caught canoodling at a Coldplay concert. "The events of the past few days have received a level of media attention that few companies—let alone startups in our small corner of the data and AI world—ever encounter," Interim CEO Pete DeJoy wrote in a LinkedIn post on Monday. "The spotlight has been unusual and surreal for our team and, while I would never have wished for it to happen like this, Astronomer is now a household name." The New York-based company's former leader, Andy Byron, and its Chief People Officer, Kristin Cabot, were seen embracing on a jumbo screen during a Coldplay concert at Gillette Stadium in Foxborough, Massachusetts on July 16. Both are married, and the incident resulted in a viral firestorm. "At Astronomer we have never shied away from challenges; a near-decade of building this business has tested us time and time again, and each time we've emerged stronger," DeJoy's statement said. "From starting a software company in Cincinnati, Ohio, to keeping the lights on through the collapse of the bank that held all our cash, to scaling from 30 to 300 people during a global pandemic that demanded we do it all without ever being in the same room." The duo reacted with horror when they saw themselves on camera, with Cabot covering her face and turning away, and Byron ducking behind a barrier. "Oh, look at these two," Coldplay front man Chris Martin said jokingly to the crowd. "All right, c'mon, you're Ok. Oh, what? Either they're having an affair or they're just very shy." Byron resigned on Saturday. "As stated previously, Astronomer is committed to the values and culture that have guided us since our founding," the company wrote in a statement Saturday to Fox News. "Our leaders are expected to set the standard in both conduct and accountability, and recently, that standard was not met." Astronomer announced an internal investigation. The company is valued at $1.3 billion and is backed by titans like Bain Capital, Salesforce and JPMorgan. Originally published as Coldplay concert cheating scandal: Interim Astronomer CEO embraces company's public spotlight in wake of kiss cam controversy
News.com.au
2 hours ago
- News.com.au
Health Check: Bug buster Genetic Signatures' US expansion is a jumbo-sized task
Genetic's company-making US expansion proves harder than expected BTC Health makes a (literally) lifesaving sale The lessons from Sarepta's billion-dollar FDA woes Gut disease diagnostics provider Genetic Signatures (ASX:GSS) is finding its US market entry more elephantine than first envisaged and has made some changes 'to better align with current strategy and needs'. On June 4 last year the US Food and Drug Administration (FDA) approved Genetic's Easyscreen, which can detect eight gastrointestinal (GI) parasites accounting for 90% of all tummy bugs. On the same day the company launched a $30 million capital raise to support the US push and announced a new CEO (former Roche Diagnostics exec Allison Rossiter). Genetic expected to be selling in the US within 60 to 90 days. Today, Genetic says the US sales ramp-up has been 'impacted by prospective customers' internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment.' In part, the company discovered that clients craved more automated sample processing. In response, Genetic has entered a three-way 'strategic partnership' with a mob called Tecan (lab automation) and Repado (compliant in vitro diagnostics). This threesome will result in a 'scalable suite of fully automated diagnostic platforms for syndromic testing labs'. Genetic doesn't mention any dollars, so we presume the financial impact is immaterial. Speaking of finances, Genetic today reported June quarter sales of $4.4 million. This was 52% higher than the March stanza, reflecting higher seasonal testing during the Australian flu season. But turnover was flat on a year-on-year comp. Having expended a net $5.95 million, Genetic ended the quarter with still-healthy cash of $30.9 million. Microba GI testing sales are on tract Still on tummy bugs, microbiome testing outfit Microba Life Sciences (ASX:MAP) has met its guidance with full-year revenue of $15.67 million, 30% higher year on year. June (fourth) quarter revenue fell 13.5% to $4.2 million, the result of the company shedding a non-core research services business. Microba has commercialised two clinical tests, to assess and manage GI patients. The flagship Metaxplore tests assess a range of markers to appraise the GI tract and presents the results in a clear report. Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics. Currently Metaxplore is sold in Australia and the UK, while Metapanel is available locally via the company's partner and biggest shareholder, Sonic Healthcare (ASX:SHL). Microba chief Dr Luke Reid says Microba has a 'well considered plan' for US rollout, based on creating a beachhead in one city. Mayne they could swap notes with Genetic's management. Locally Microba sold 3451 Metaexplore tests during the quarter, up 88%. Microba also sold 266 Metapanel tests here (up 85%) and 429 in the UK (the test was only launched there in May). Microba recorded net cash outflows of $5.56 million for the quarter, but management affirms the Australian and UK ops should be break-even this year. BTC Health's PDF format suits investors One of the more unusual life science plays on the bourse, medical product distributor BTC Health (ASX:BTC) has secured a $500,000 equipment order with Adelaide's Women's and Children's Hospital. The order is for extracorporeal membrane oxygenation (ECMO) and follows a similar deal with Melbourne's Royal Children's Hospital. ECMOs take over the work of the heart and lungs when these organs cannot perform their duties. BTC Health is building a portfolio of diverse yet specialist medical devices, such as heart valves and infusion pumps. BTC is a valuable pooled development fund (PDF), a remnant of a Keating-era initiative to bolster investment in small business. PDFs pay only 15% tax on income and capital gains, but any returns to shareholders are tax free. Only 17 PFDs remain and – like coastal property – God is not creating any more of them. BTC chief Dr Richard Treagus previously headed generic drug play Acrux, the sector's only other PDF. BTC posted December half revenue of $5.3 million, with underlying earnings of $200,000. The company expects to have remained in the black for the full year to June 30 with a 'pathway to sustainable growth'. Sarepta 'is worth nothing' Could a $US1.31 billion company really be worth nothing? US investment bank H.C. Wainwright thinks so, having ascribed a 'price target' of yada and zip to the Sarepta Therapeutics on the back of the Nasdaq-listed entity's drug strife. Last week the FDA asked Sarepta to voluntarily halt shipments of its Elevidys gene therapy, for muscular dystrophy. This follows the death of two patients from liver toxicity issues and the third from a separate experimental gene therapy treatment. Defying the agency, Sarepta said it would continue to ship the therapy to ambulatory patients, but maintain a halt for wheelchair-bound ones. The deaths pertained to the latter. The FDA approved Elevidys two years ago for walking patients aged four or older, with the Duchenne muscular dystrophy (DMD) gene mutation. A year later the agency expanded the assent to non-ambulatory patients. Sarepta shares shed up to 40% on Friday and a further 5% overnight. Don't fight City Hall H.C. Wainwright previously had a US$10 valuation on Sarepta, compared with the stock's overnight close of US$13.32. The firm describes Sarepta's fight with the FDA as 'unwinnable' and – indeed – you can't beat City Hall. Elevidys generated US$384 million of net revenue in the December quarter, more than half of Sarepta's total revenue of US$638 million. The lesson for everyone is that even when drug makers have done the hard yards of developing and commercialising a therapy, success is still not guaranteed. In one of the best-known cases, in 1999 the FDA approved Merck's Vioxx, for osteoarthritis pain. After racking up billions in sales Merck withdrew the drug from sale in 2004, amid concerns it could cause heart attacks and strokes. Locally, Percheron Therapeutics (ASX:PER) is reinventing itself after its DMD therapy failed in phase IIb stage last December. Perhaps the company dodged a bullet by discovering the problems early in the piece, but wounded investors might disagree.
Perth Now
2 hours ago
- Perth Now
Australian shares gain as miners rise, banks fall
The local share market has moved modestly higher as rotation continues from Australia's expensive banks to its major miners. At midday on Tuesday, the benchmark S&P/ASX200 index was up 15.5 points, or 0.18 per cent, to 8,683.7, while the broader All Ordinaries had gained 20 points, or 0.22 per cent, to 8,946.2. Traders were digesting minutes from the Reserve Bank's July 7-8 meeting, in which the central bank surprised observers by leaving interest rates on hold rather than trimming them. The minutes said most board members felt cutting rates for a third time in the space of four meetings "would be unlikely to be consistent with the strategy of easing monetary policy in a cautious and gradual manner to achieve the Board's inflation and full employment objectives". Market participants were also pondering the reason for Monday's 1.0 per cent pullback, which followed a 1.37 per cent rally on Friday that had left the index at its highest level ever. Monday's heavy selloff following Friday's all-time high mirrored a pattern that had occurred around half a dozen times last year, IG analyst Tony Sycamore said. "While I find this pattern intriguing, I am still struggling to explain the rationale behind it," he wrote. In the absence of a better theory, it is possible Monday's pullback was profit-taking ahead of the August earnings season that is likely to highlight stretched valuations in certain sectors, particularly the banks, Mr Sycamore said. The ASX's financial sector was the worst performing at midday, down 1.2 per cent, while the materials/mining sector was the best performing, up 1.9 per cent. All four of the big retail banks were in the red with CBA down 2.0 per cent, NAB falling 1.6 per cent and Westpac and ANZ both dipping 1.1 per cent, while all of the major miners were in the green. BHP had grown 2.4 per cent, Fortescue had advanced 2.5 per cent and Rio Tinto had added 2.7 per cent. Goldminers were also doing well as the yellow metal traded for a one-month high of just over $US3,400 an ounce. Newmont had advanced 2.7 per cent, Evolution had risen 2.2 per cent and Emerald Resources had added 4.9 per cent. Back in the financial sector, Insignia had soared 11.5 per cent to $4.38 after the company formerly known as IOOF agreed to be acquired by a US-based private equity firm for $3.2 billion. CC Capital will pay $4.80 a share, a 56.9 per cent premium from Insignia's share price in December when news of its interest first became public, but less than the $5 per share price that CC lobbed in March. The Australian dollar meanwhile was buying 65.22 US cents, from 65.17 US cents around 5pm on Monday.
